STING activation as a therapeutic tool for GBM treatment has recently been explored in preclinical murine and canine models with encouraging tumor responses that might be related to STING-mediated remodeling of the tumor microenvironment [48,49]. The gene discussed is STING1; the disease is neoplasm.